Delivery of diagnostic agents for magnetic resonance imaging

Advanced Drug Delivery Reviews

Volumn 37, Issue 1-3, 1999, Pages 121-137

  Okuhata, Yoshitaka ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Capillary permeability; Contrast agent; Contrast enhancement; Contrast media; Diagnosis; Drug delivery; Tissue distribution

Indexed keywords

AGENTS; ANTIBODIES; CAPILLARITY; CELLS; CONTRAST MEDIA; DIAGNOSTIC RADIOGRAPHY; MAGNETIC RESONANCE IMAGING; METABOLISM; NUCLEAR MEDICINE; TISSUE;

BLOOD POOL; CAPILLARY PERMEABILITY; CONTRAST ENHANCEMENT; DIAGNOSTIC AGENTS; TISSUE DISTRIBUTION;

CONTROLLED DRUG DELIVERY;

ANTIBODY; DIAGNOSTIC AGENT; DRUG CARRIER; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GASTROINTESTINAL AGENT; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RECEPTOR;

BLOOD; CAPILLARY PERMEABILITY; CONTRAST ENHANCEMENT; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MAGNETISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TISSUE DISTRIBUTION;

EID: 0344958763     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00103-3     Document Type: Review

References (148)

1. R.F. Mattrey, M.A. Trambert, J.J. Brown, S.W. Young, J.N. Bruneton, G.E. Wesbey, Z.N. Balsara, Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial, Radiology 191 (1994) 841-848.
2. R.N. Low, I.R. Francis, MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT, Am. J. Roentgenol. 169 (1997) 1051-1059.
3. H.J. Weinmann, R.C. Brasch, W.R. Press, G.E. Wesbey, Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent, Am. J. Roentgenol. 142 (1984) 619-624.
4. A. Greco, M.T. McNamara, P. Lanthiez, S.C. Quay, G. Michelozzi, Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine - phase II-III clinical trial, Radiology 176 (1990) 451-456.
5. J.C. Bousquet, S. Saini, D.D. Stark, P.F. Hahn, M. Nigam, J. Wittenberg, J.T. Ferrucci Jr., Gd-DOTA: characterization of a new paramagnetic complex, Radiology 166 (1988) 693-698.
6. V.M. Runge, B. Dean, C. Lee, F. Carolan, G. Heard, Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease, J. Magn. Reson. Imaging 1 (1991) 47-56.
7. E.C. Wiener, M.W. Brechbiel, H. Brothers, R.L. Magin, O.A. Gansow, D.A. Tomalia, P.C. Lauterbur, Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents, Magn. Reson. Med. 31 (1994) 1-8.
8. K. Orang Khadivi, B.L. Pierce, C.M. Ollom, L.J. Floyd, R.L. Siegle, R.F. Williams, New magnetic resonance imaging techniques for the detection of breast cancer, Breast Cancer Res. Treat. 32 (1994) 119-135.
9. G. Marchal, H. Bosmans, P. Van Hecke, U. Speck, P. Aerts, P. Vanhoenacker, A.L. Baert, MR angiography with gadopentetate dimeglumine-polylysine: evaluation in rabbits, Am. J. Roentgenol. 155 (1990) 407-411.
10. M.H. Mendonca Dias, E. Gaggelli, P.C. Lauterbur, Paramagnetic contrast agents in nuclear magnetic resonance medical imaging, Semin. Nucl. Med. 13 (1983) 364-376.
11. M.G. Wikstrom, D.L. White, M.E. Moseley, J.W. Dupon, R.C. Brasch, Ascorbate-induced cancellation of nitroxide contrast media enhancement of MR images, Invest. Radiol. 24 (1989) 692-696.
12. G. Bacic, K.J. Liu, F. Goda, P.J. Hoopes, G.M. Rosen, H.M. Swartz, MRI contrast enhanced study of cartilage proteoglycan degradation in the rabbit knee, Magn. Reson. Med. 37 (1997) 764-768.
13. R. Weissleder, G. Elizondo, J. Wittenberg, C.A. Rabito, H.H. Bengele, L. Josephson, Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging, Radiology 175 (1990) 489-493.
14. T. Shen, R. Weissleder, M. Papisov, A. Bogdanov Jr., T.J. Brady, Monocrystalline iron oxide nanocompounds (MION): physicochemical properties, Magn. Reson. Med. 29 (1993) 599-604.
15. A.D. Nunn, K.E. Linder, M.F. Tweedle, Can receptors be imaged with MRI agents? Q. J. Nucl. Med. 41 (1997) 155-162.
16. E.C. Wiener, S. Konda, A. Shadron, M.W. Brechbiel, O. Gansow, Targeting dendrimer-chelate to tumors and tumor cells expressing the high-affinity folate receptor, Invest. Radiol. 32 (1997) 748-754.
17. P. Reimer, R. Weissleder, T. Shen, W.T. Knoefel, T.J. Brady, Pancreatic receptors: initial feasibility studies with a targeted contrast agent for MR imaging, Radiology 193 (1994) 527-531.
18. T.H. Pels Rijcken, M.A. Davis, P.R. Ros, Intraluminal contrast agents for MR imaging of the abdomen and pelvis, J. Magn. Reson. Imaging 4 (1994) 291-300.
19. J.J. Brown, Gastrointestinal contrast agents for MR imaging, Magn. Reson. Imaging Clin. N. Am. 4 (1996) 25-35.
20. R.W. Briggs, Z. Wu, C.R. Mladinich, C. Stoupis, J. Gauger, T. Liebig, P.R. Ros, J.R. Ballinger, P. Kubilis, In vivo animal tests of an artifact-free contrast agent for gastrointestinal MRI, Magn. Reson. Imaging 15 (1997) 559-566.
21. T. Xia, Y. Okuhata, S. Urahashi, Y. Tanaka, Intraoral MR lymphography: a new method for selective enhanced detection of the cervical lymph nodes, Nippon-Igaku-Hoshasen-Gakkai-Zasshi 55 (1995) 488-492.
22. Y. Anzai, S. McLachlan, M. Morris, R. Saxton, R.B. Lufkin, Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck, Am. J. Neuroradiol. 15 (1994) 87-94.
23. R. Weissleder, G. Elizondo, L. Josephson, C.C. Compton, C.J. Fretz, D.D. Stark, J.T. Ferrucci, Experimental lymph node metastases: enhanced detection with MR lymphography, Radiology 171 (1989) 835-839.
24. M. Taupitz, S. Wagner, B. Hamm, A. Binder, D. Pfefferer, Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits, Am. J. Roentgenol. 161 (1993) 193-200.
25. V.S. Trubetskoy, J.A. Cannillo, A. Milshtein, G.L. Wolf, V.P. Torchilin, Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties, Magn. Reson. Imaging 13 (1995) 31-37.
26. B. Misselwitz, A. Sachse, Interstitial MR lymphography using Gd-carrying liposomes, Acta Radiol. Suppl. 412 (1997) 51-55.
27. Y. Berthezene, V. Vexler, O. Clement, A. Muhler, M.E. Moseley, R.C. Brasch, Contrast-enhanced MR imaging of the lung: assessments of ventilation and perfusion, Radiology 183 (1992) 667-672.
28. R.R. Edelman, H. Hatabu, E. Tadamura, W. Li, P.V. Prasad, Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging, Nat. Med. 2 (1996) 1236-1239.
29. B. Misselwitz, A. Muhler, I. Heinzelmann, J.C. Bock, H.J. Weinmann, Magnetic resonance imaging of pulmonary ventilation. Initial experiences with a gadolinium-DTPA-based aerosol, Invest. Radiol. 32 (1997) 797-801.
30. Y. Okuhata, T. Xia, S. Urahashi, Inhalation MR lymphography: a new method for selective enhancement of the lung hilar and mediastinal lymph nodes, Magn. Reson. Imaging 12 (1994) 1135-1138.
31. W.S. Enochs, B. Schaffer, P.G. Bhide, N. Nossiff, M. Papisov, A. Bogdanov Jr., T.J. Brady, R. Weissleder, MR imaging of slow axonal transport in vivo, Exp. Neurol. 123 (1993) 235-242.
32. K.J. van Everdingen, W.S. Enochs, P.G. Bhide, N. Nossiff, M. Papisov, A. Bogdanov Jr., T.J. Brady, R. Weissleder, Determinants of in vivo MR imaging of slow axonal transport, Radiology 193 (1994) 485-491.
33. R.C. Brasch, Rationale and applications for macromolecular Gd-based contrast agents, Magn. Reson. Med. 22 (1991) 282-287.
34. T.S. Desser, D.L. Rubin, H.H. Muller, F. Qing, S. Khodor, G. Zanazzi, S.W. Young, D.L. Ladd, J.A. Wellons, K.E. Kellar, et al., Dynamics of tumor imaging with Gd-DTPA-polyethylene glycol polymers: dependence on molecular weight, J. Magn. Reson. Imaging 4 (1994) 467-472.
35. V.S. Vexler, O. Clement, H. Schmitt Willich, R.C. Brasch, Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns, J. Magn. Reson. Imaging 4 (1994) 381-388.
36. U. Schmiedl, M.E. Moseley, M.D. Ogan, W.M. Chew, R.C. Brasch, Comparison of initial biodistribution patterns of Gd-DTPA and albumin-(Gd-DTPA) using rapid spin echo MR imaging, J. Comput. Assist. Tomogr. 11 (1987) 306-313.
37. M.D. Ogan, U. Schmiedl, M.E. Moseley, W. Grodd, H. Paajanen, R.C. Brasch, Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization, Invest. Radiol. 22 (1987) 665-671.
38. U. Schmiedl, M.E. Moseley, R. Sievers, M.D. Ogan, W.M. Chew, H. Engeseth, W.E. Finkbeiner, M.J. Lipton, R.C. Brasch, Magnetic resonance imaging of myocardial infarction using albumin-(Gd-DTPA), a macromolecular blood-volume contrast agent in a rat model, Invest. Radiol. 22 (1987) 713-721.
39. V.S. Vexler, Y. Berthezene, O. Clement, A. Muhler, W. Rosenau, M.E. Moseley, R.C. Brasch, Detection of zonal renal ischemia with contrast-enhanced MR imaging with a macromolecular blood pool contrast agent, J. Magn. Reson. Imaging 2 (1992) 311-319.
40. R. Brasch, C. Pham, D. Shames, T. Roberts, K. van Dijke, N. van Bruggen, J. Mann, S. Ostrowitzki, O. Melnyk, Assessing tumor angiogenesis using macromolecular MR imaging contrast media, J. Magn. Reson. Imaging 7 (1997) 68-74.
41. C.F. van Dijke, R.C. Brasch, T.P. Roberts, N. Weidner, A. Mathur, D.M. Shames, J.S. Mann, F. Demsar, P. Lang, H.C. Schwickert, Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density, Radiology 198 (1996) 813-818.
42. H. Daldrup, D.M. Shames, M. Wendland, Y. Okuhata, T.M. Link, W. Rosenau, Y. Lu, R.C. Brasch, Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media, Pediatr. Radiol. 28 (1998) 67-78.
43. W.A. Gibby, A. Bogdan, T.W. Ovitt, Cross-linked DTPA polysaccharides for magnetic resonance imaging. Synthesis and relaxation properties, Invest. Radiol. 24 (1989) 302-309.
44. S.C. Wang, M.G. Wikstrom, D.L. White, J. Klaveness, E. Holtz, P. Rongved, M.E. Moseley, R.C. Brasch, Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues, Radiology 175 (1990) 483-488.
45. F.E. Armitage, D.E. Richardson, K.C. Li, Polymeric contrast agents for magnetic resonance imaging: synthesis and characterization of gadolinium diethylenetriaminepentaacetic acid conjugated to polysaccharides, Bioconjug. Chem. 1 (1990) 365-374.
46. R. Rebizak, M. Schaefer, E. Dellacherie, Polymeric conjugates of Gd(3+)-diethylenetriaminepentaacetic acid and dextran. 1. Synthesis, characterization, and paramagnetic properties, Bioconjug. Chem. 8 (1997) 605-610.
47. Y. Berthezene, V. Vexler, H. Jerome, R. Sievers, M.E. Moseley, R.C. Brasch, Differentiation of capillary leak and hydrostatic pulmonary edema with a macromolecular MR imaging contrast agent, Radiology 181 (1991) 773-777.
48. R.C. Brasch, New directions in the development of MR imaging contrast media, Radiology 183 (1992) 1-11.
49. T.H. Lim, D.H. Lee, Y.H. Kim, S.W. Park, P.H. Park, D.M. Seo, S.T. Kim, T.K. Lee, C.W. Mun, Occlusive and reperfused myocardial infarction: detection by using MR imaging with gadolinium polylysine enhancement, Radiology 189 (1993) 765-768.
50. A.A. Bogdanov Jr., R. Weissleder, H.W. Frank, A.V. Bogdanova, N. Nossif, B.K. Schaffer, E. Tsai, M.I. Papisov, T.J. Brady, A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies, Radiology 187 (1993) 701-706.
51. H. Gupta, R.A. Wilkinson, A.A. Bogdanov Jr., R.J. Callahan, R. Weissleder, Inflammation: imaging with methoxy poly(ethylene glycol)-poly-L-lysine-DTPA, a long-circulating graft copolymer, Radiology 197 (1995) 665-669.
52. G. Adam, J. Neuerburg, E. Spuntrup, A. Muhler, K. Scherer, R.W. Gunther, Gd-DTPA-cascade-polymer: potential blood pool contrast agent for MR imaging, J. Magn. Reson. Imaging 4 (1994) 462-466.
53. N. Siauve, O. Clement, C.A. Cuenod, S. Benderbous, G. Frija, Capillary leakage of a macromolecular MRI agent, carboxymethyldextran-Gd-DTPA, in the liver: pharmacokinetics and imaging implications, Magn. Reson. Imaging 14 (1996) 381-390.
54. C. Corot, M. Schaefer, S. Beaute, P. Bourrinet, S. Zehaf, V. Benize, M. Sabatou, D. Meyer, Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA. A new paramagnetic dextran polymer, Acta Radiol. Suppl. 412 (1997) 91-99.
55. G. Tian, J. Shen, S. Su, P. Kozlowski, J. Sun, B. Xiang, J.K. Saunders, R. Deslauriers, Evaluation of hydroxyethyl-starchferrioxamine as an intravascular MR contrast agent for assessment of myocardial perfusion, Acta Radiol. Suppl. 412 (1997) 85-90.
56. S. Pochon, R. Hyacinthe, J. Terrettaz, F. Robert, M. Schneider, H. Tournier, Long circulating superparamagnetic particles with high T2 relaxivity, Acta Radiol. Suppl. 412 (1997) 69-72.
57. R. Weissleder, D.D. Stark, B.L. Engelstad, B.R. Bacon, C.C. Compton, D.L. White, P. Jacobs, J. Lewis, Superparamagnetic iron oxide: pharmacokinetics and toxicity, Am. J. Roentgenol. 152 (1989) 167-173.
58. B. Hamm, T. Staks, M. Taupitz, R. Maibauer, A. Speidel, A. Huppertz, T. Frenzel, R. Lawaczeck, K.J. Woff, L. Lange, Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide, J. Magn. Reson. Imaging 4 (1994) 659-668.
59. T.J. Vogl, R. Hammerstingl, W. Schwarz, S. Kummel, P.K. Muller, T. Balzer, M.J. Lauten, J.O. Balzer, M.G. Mack, C. Schimpfky, H. Schrem, W.O. Bechstein, P. Neuhaus, R. Felix, Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient, Invest. Radiol. 31 (1996) 696-708.
60. L. Josephson, J. Lewis, P. Jacobs, P.F. Hahn, D.D. Stark, The effects of iron oxides on proton relaxivity, Magn. Reson. Imaging 6 (1988) 647-653.
61. H.H. Bengele, S. Palmacci, J. Rogers, C.W. Jung, J. Crenshaw, L. Josephson, Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration, Magn. Reson. Imaging 12 (1994) 433-442.
62. L. Harika, R. Weissleder, K. Poss, M.I. Papisov, Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies, Radiology 198 (1996) 365-370.
63. R. Guimaraes, O. Clement, J. Bittoun, F. Carnot, G. Frija, MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement, Am. J. Roentgenol. 162 (1994) 201-207.
64. P. Vassallo, C. Matei, W.D. Heston, S.J. McLachlan, J.A. Koutcher, R.A. Castellino, AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes, Radiology 193 (1994) 501-506.
65. R. Weissleder, J.F. Heautot, B.K. Schaffer, N. Nossiff, M.I. Papisov, A. Bogdanov Jr., T.J. Brady, MR lymphography: study of a high-efficiency lymphotrophic agent, Radiology 191 (1994) 225-230.
66. E. Unger, P. Needleman, P. Cullis, C. Tilcock, Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress, Invest. Radiol. 23 (1988) 928-932.
67. C. Tilcock, E. Unger, P. Cullis, P. MacDougall, Liposomal Gd-DTPA: preparation and characterization of relaxivity, Radiology 171 (1989) 77-80.
68. G.W. Kabalka, M.A. Davis, T.H. Moss, E. Buonocore, K. Hubner, E. Holmberg, K. Maruyama, L. Huang, Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver, Magn. Reson. Med. 19 (1991) 406-415.
69. T. Fritz, E. Unger, S. Wilson-Sanders, Q.F. Ahkong, C. Tilcock, Detailed toxicity studies of liposomal gadolinium-DTPA, Invest. Radiol. 26 (1991) 960-968.
70. M.D. Bednarski, J.W. Lee, M.R. Callstrom, K.C. Li, In vivo target-specific delivery of macromolecular agents with MR-guided focused ultrasound, Radiology 204 (1997) 263-268.
71. E.R. Wisner, K.L. Aho Sharon, M.J. Bennett, S.G. Penn, C.B. Lebrilla, M.H. Nantz, A modular lymphographic magnetic resonance imaging contrast agent: contrast enhancement with DNA transfection potential, J. Med. Chem. 40 (1997) 3992-3996.
72. R. Weissleder, P. Reimer, A.S. Lee, J. Wittenberg, T.J. Brady, MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors, Am. J. Roentgenol. 155 (1990) 1161-1167.
73. P. Reimer, R.Weissleder, A.S. Lee, J. Wittenberg, T.J. Brady, Receptor imaging: application to MR imaging of liver cancer, Radiology 177 (1990) 729-734.
74. B.K. Schaffer, C. Linker, M. Papisov, E. Tsai, N. Nossiff, T. Shibata, A. Bogdanov Jr., T.J. Brady, R. Weissleder, MION-ASF: biokinetics of an MR receptor agent, Magn. Reson. Imaging 11 (1993) 411-417.
75. D.R. Vera, M.H. Buonocore, E.R. Wisner, R.W. Katzberg, R.C. Stadalnik, A molecular receptor-binding contrast agent for magnetic resonance imaging of the liver, Acad. Radiol. 2 (1995) 497-506.
76. A.L. Schwartz, D. Rup, H.F. Lodisch, Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte, J. Biol. Chem. 255 (1980) 9033-9036.
77. H. Tolleshaug, Binding and internalization of asialoglycoprotein by isolated rat hepatocytes, Int. J. Biochem. 13 (1981) 45-51.
78. P. Reimer, R. Weissleder, A.S. Lee, S. Buettner, J. Wittenberg, T.J. Brady, Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging, Radiology 178 (1991) 769-774.
79. C.R. Leveille Webster, J. Rogers, I.M. Arias, Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats, Hepatology 23 (1996) 1631-1641.
80. T.T. Shen, A. Bogdanov Jr., A. Bogdanova, K. Poss, T.J. Brady, R. Weissleder, Magnetically labeled secretin retains receptor affinity to pancreas acinar cells, Bioconjug. Chem. 7 (1996) 311-316.
81. L.X. Tiefenauer, A. Tschirky, G. Kuhne, R.Y. Andres, In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI, Magn. Reson. Imaging 14 (1996) 391-402.
82. R. Weissleder, A.S. Lee, A.J. Fischman, P. Reimer, T. Shen, R. Wilkinson, R.J. Callahan, T.J. Brady, Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging, Radiology 181 (1991) 245-249.
83. G. Schuhmann Giampieri, Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging, Invest. Radiol. 28 (1993) 753-761.
84. R.B. Lauffer, A.C. Vincent, S. Padmanabhan, A. Villringer, S. Saini, D.R. Elmaleh, T.J. Brady, Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives, Magn. Reson. Med. 4 (1987) 582-590.
85. P. Pavone, G. Patrizio, C. Buoni, E. Tettamanti, R. Passariello, C. Musu, P. Tirone, E. Felder, Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver, Radiology 176 (1990) 61-64.
86. T.J. Vogl, W. Pegios, C. McMahon, J. Balzer, J. Waitzinger, G. Pirovano, J. Lissner, Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers, Am. J. Roentgenol. 158 (1992) 887-892.
87. H.J. Weinmann, G. Schuhmann Giampieri, H. Schmitt Willich, H. Vogler, T. Frenzel, H. Gries, A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI, Magn. Reson. Med. 22 (1991) 233-237.
88. B. Hamm, T. Staks, A. Muhler, M. Bollow, M. Taupitz, T. Frenzel, K.J. Wolf, H.J. Weinmann, L. Lange, Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging, Radiology 195 (1995) 785-792.
89. R. Kuwatsuru, M. Kadoya, A. Tanimoto, S. Hirohashi, H. Katayama, [Early phase II trial of Gd-BOPTA (E7155) for the MR imaging of liver tumors], Nippon-Igaku-Hoshasen-Gakkai-Zasshi 56 (1996) 555-563.
90. P. Reimer, E.J. Rummeny, K. Shamsi, T. Balzer, H.E. Daldrup, B. Tombach, T. Hesse, T. Berns, P.E. Peters, Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence, Radiology 199 (1996) 177-183.
91. O. Clement, A. Muhler, V. Vexler, Y. Berthezene, R.C. Brasch, Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats, Invest. Radiol. 27 (1992) 612-619.
92. A. Muhler, C.E. Preise, R. Kuwatsuru, W. Rosenau, T. Liu, J. Mintorovitch, O. Clement, V. Vexler, S. Mahboubi, P. Lang, et al., Acute liver rejection: evaluation with cell-directed MR contrast agents in a rat transplantation model, Radiology 186 (1993) 139-146.
93. A. Muffler, I. Heinzelmann, H.J. Weinmann, Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats, Invest. Radiol. 29 (1994) 213-216.
94. C. Petre, Y. Ni, G. Marchal, J. Yu, M. Wevers, R.B. Lauffer, A.L. Baert, Detection and characterization of primary liver cancer in rats by MS-264-enhanced MRI, Magn. Reson. Med. 35 (1996) 532-539.
95. M.E. Bernardino, S.W. Young, J.K. Lee, J.C. Weinreb, Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity, Radiology 183 (1992) 53-58.
96. K.O. Lim, D.D. Stark, P.T. Leese, A. Pfefferbaum, S.M. Rocklage, S.C. Quay, Hepatobiliary MR imaging: first human experience with MnDPDP, Radiology 178 (1991) 79-82.
97. S.M. Rocklage, W.P. Cacheris, C.S. Quay, F.E. Hahn, K.N. Raymond, Manganese (II) N,N′-dipyridoxylethylenediamine-N, N′-diacetate 5,5′-Bis(phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement, Inorg. Chem. 28 (1989) 477-485.
98. H.B. Gehl, D. Vorwerk, K.C. Mose, R.W. Gunther, Pancreatic enhancement after low-dose infusion of Mn-DPDP, Radiology 180 (1991) 337-339.
99. D.G. Mitchell, E.K. Outwater, T. Matteucci, D.L. Rubin, J.L. Chezmar, S. Saini, Adrenal gland enhancement at MR imaging with Mn-DPDP, Radiology 194 (1995) 783-787.
100. O.H. Pomeroy, M. Wendland, S. Wagner, N. Derugin, W.W. Holt, S.M. Rocklage, S. Quay, C.B. Higgins, Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, Mn-DPDP, Invest. Radiol. 24 (1989) 531-536.
101. B. Gallez, G. Bacic, H.M. Swartz, Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP, Magn. Reson. Med. 35 (1996) 14-19.
102. B. Gallez, C. Baudelet, J. Adline, M. Geurts, N. Delzenne, Accumulation of manganese in the brain of mice after intravenous injection of manganese-based contrast agents, Chem. Res. Toxicol. 10 (1997) 360-363.
103. I.K. Adzamli, H. Gries, D. Johnson, M. Blau, Development of phosphonate derivatives of gadolinium chelates for NMR imaging of calcified soft tissues, J. Med. Chem. 32 (1989) 139-144.
104. I.K. Adzamli, M. Blau, M.A. Pfeffer, M.A. Davis, Phosphonate-modified Gd-DTPA complexes. III: The detection of myocardial infarction by MRI, Magn. Reson. Med. 29 (1993) 505-511.
105. K. Adzamli, H. Mei, J.A. Leppo, Macromolecular infarctspecific magnetic resonance contrast agents, Invest. Radiol. 29 (1994) 515-517.
106. R. Weissleder, Y.M. Wang, M. Papisov, A. Bogdanov, B. Schaffer, T.J. Brady, J. Wittenberg, Polymeric contrast agents for MR imaging of adrenal glands, J. Magn. Reson. Imaging 3 (1993) 93-97.
107. A. Muhler, J. Platzek, B. Raduchel, T. Frenzel, H.J. Weinmann, Characterization of a gadolinium-labeled cholesterol derivative as an organ-specific contrast agent for adrenal MR imaging, J. Magn. Reson. Imaging 5 (1995) 7-10.
108. C. Kosmas, H. Linardou, A.A. Epenetos, Review: advances in monoclonal antibody tumour targeting, J. Drug Target 1 (1993) 81-91.
109. E.C. Unger, W.G. Totty, D.M. Neufeld, F.L. Otsuka, W.A. Murphy, M.S. Welch, J.M. Connett, G.W. Philpott, Magnetic resonance imaging using gadolinium labeled monoclonal antibody, Invest. Radiol. 20 (1985) 693-700.
110. W.T. Anderson Berg, M. Strand, T.E. Lempert, A.E. Rosenbaum, P.M. Joseph, Nuclear magnetic resonance and gamma camera tumor imaging using gadolinium-labeled monoclonal antibodies, J. Nucl. Med. 27 (1986) 829-833.
111. P.F. Renshaw, C.S. Owen, A.E. Evans, J.S. Leigh Jr., Immunospecific NMR contrast agents, Magn. Reson. Imaging 4 (1986) 351-357.
112. S. Cerdan, H.R. Lotscher, B. Kunnecke, J. Seelig, Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors, Magn. Reson. Med. 12 (1989) 151-163.
113. R. Weissleder, A.S. Lee, B.A. Khaw, T. Shen, T.J. Brady, Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging, Radiology 182 (1992) 381-385.
114. L.G. Remsen, C.I. McCormick, S. Roman Goldstein, G. Nilaver, R. Weissleder, A. Bogdanov, I. Hellstrom, R.A. Kroll, F.A. Neuwelt, MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis, Am. J. Neuroradiol. 17 (1996) 411-418.
115. M. Suzuki, H. Honda, T. Kobayashi, T. Wakabayashi, J. Yoshida, M. Takahashi, Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles, Noshuyo-Byori 13 (1996) 127-132.
116. S.E. Kornguth, P.A. Turski, W.H. Perman, R. Schultz, T. Kalinke, R. Reale, F. Raybaud, Magnetic resonance imaging of gadolinium-labeled monoclonal antibody polymers directed at human T lymphocytes implanted in canine brain, J. Neurosurg. 66 (1987) 898-906.
117. S. Gohr-Rosenthal, H. Schmitt-Willich, W. Ebert, J. Conrad, The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging, Invest. Radiol. 28 (1993) 789-795.
118. T. Suwa, S. Ozawa, M. Ueda, N. Ando, M. Kitajima, Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody, Int. J. Cancer 75 (1998) 626-634.
119. T.W. Chan, C. Eley, P. Liberti, A. So, H.Y. Kressel, Magnetic resonance imaging of abscesses using lipid-coated iron oxide particles, Invest. Radiol. 27 (1992) 443-449.
120. R. Weissleder, H.C. Cheng, A. Bogdanova, A. Bogdanov Jr., Magnetically labeled cells can be detected by MR imaging, J. Magn. Reson. Imaging 7 (1997) 258-263.
121. T.C. Yeh, W. Zhang, S.T. Ildstad, C. Ho, Intracellular labeling of T-cells with superparamagnetic contrast agents, Magn. Reson. Med. 30 (1993) 617-625.
122. J.W. Bulte, L.D. Ma, R.L. Magin, R.L. Kamman, C.E. Hulstaert, K.G. Go, T.H. The, L. de Leij, Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles, Magn. Reson. Med. 29 (1993) 32-37.
123. J.A. Nelson, U. Schmiedl, Porphyrins as contrast media, Magn. Reson. Med. 22 (1991) 366-371.
124. S.W. Young, M.K. Sidhu, F. Qing, H.H. Muller, M. Neuder, G. Zanassi, T.D. Mody, G. Hemmi, W. Dow, J.D. Mutch, et al., Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging, Invest. Radiol. 29 (1994) 330-338.
125. S.W. Young, Q. Fan, D.M. Kunis, G.K. Steinberg, Experimental acute cerebral ischemia with reperfusion. Evaluation with gadolinium-texaphyrin, Invest. Radiol. 31 (1996) 353-358.
126. G. Marchal, Y. Ni, P. Herijgers, W. Flameng, C. Petre, H. Bosmans, J. Yu, W. Ebert, C.S. Hilger, D. Pfefferer, W. Seminler, A.L. Baert, Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by MRI, Eur. Radiol. 6 (1996) 2-8.
127. Y. Ni, C. Petre, T. Miao, J. Yu, E. Cresens, A.L. Baert, G. Marchal, Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis, Invest. Radiol. 32 (1997) 770-779.
128. A. Matsumura, Y. Shibata, T. Yamamoto, K. Nakagawa, S. Yasuda, S. Nakajima, I. Sakata, T. Yoshizawa, T. Nose, Mn-metalloporphyrin conjugated with Gd-DTPA (Gd-ATN10): tumor enhancement agent for magnetic resonance imaging, Neurol. Med. Chir. Tokyo 37 (1997) 327-331.
129. D.J. Parmelee, R.C. Walovitch, H.S. Quellet, R.B. Lauffer, Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging, Invest. Radiol. 32 (1997) 741-747.
130. T.M. Grist, F.R. Korosec, D.C. Peters, R.C. Walovitch, E.K. Yucel, C. Misretta, Steady state and dynamic MR angiographic imaging with MS-325: initial experience in humans. Proc. Int. Soc. Mag. Res. Med. (1997) 207.
131. R.A. Moats, S.E. Fraser, T.J. Meade, A 'smart' magnetic resonance imaging agent that reports on specific enzymatic activity, Angew. Chem. Int. Ed. Engl. 36 (1997) 726-728.
132. M. Mikawa, N. Miwa, M. Brautigam, T. Akaike, A. Maruyama, A pH-sensitive contrast agent for functional magnetic resonance imaging (MRI). Chemistry Letters (1998) 693-694.
133. E.M. Renkin, C. Crone, Microcirculation and capillary exchange, in: R. Greger, U. Windhorst (Eds.), Comprehensive Human Physiology, vol. 2, Springer, Berlin, 1996, pp. 1965-1979.
134. D.N. Granger, Capillary exchange, in: L.R. Johnson (Ed.), Essential Medical Physiology, 2nd ed., Lippincott-Raven, Philadelphia, 1998, pp. 217-225.
135. W.S. Enochs, R. Weissleder, Organ- and tissue-directed MRI contrast agents, in: R.R. Edelman, J.R. Hesselink, M.B. Zlatkin (Eds.), Clinical Magnetic Resonance Imaging, 2nd ed., W.B. Saunders, Philadelphia, 1996, pp. 192-220.
136. G. Adam, A. Muhler, E. Spuntrup, J.M. Neuerburg, M. Kilbinger, H. Bauer, L. Fucezi, W. Kupper, R.W. Gunther, Differentiation of spontaneous canine breast tumors using dynamic new blood-pool agent. Preliminary experience, Invest. Radiol. 31 (1996) 267-274.
137. H.C. Roberts, M. Saeed, T.P. Roberts, A. Muhler, D.M. Shames, J.S. Mann, M. Stiskal, F. Demsar, R.C. Brasch, Comparison of albumin-(Gd-DTPA)30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability, J. Magn. Reson. Imaging 7 (1997) 331-338.
138. S. Saini, R.R. Edelman, P. Sharma, W. Li, W. Mayo Smith, G.J. Slater, P.J. Eisenberg, P.F. Hahn, Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227), Am. J. Roentgenol. 164 (1995) 1147-1152.
139. T. Tanoura, M. Bernas, A. Darkazanli, E. Elam, E. Unger, M.H. Witte, A. Green, MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis, Am. J. Roentgenol. 159 (1992) 875-881.
140. Y. Kawamura, K. Endo, Y. Watanabe, T. Saga, T. Nakai, H. Hikita, K. Kagawa, J. Konishi, Use of magnetite particles as a contrast agent for MR imaging of the liver, Radiology 174 (1990) 357-360.
141. A.A. Bogdanov Jr., C. Martin, R. Weissleder, T.J. Brady, Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes, Biochim. Biophys. Acta 1193 (1994) 212-218.
142. B.R. Rosen, T.J. Brady, Future uses of MR imaging agents, J. Comput. Assist. Tomogr. 17 (1993) 536-542.
143. B. Gallez, V. Lacour, R. Demeure, R. Debuyst, F. Dejehet, J.L. De Keyser, P. Dumont, Spin labelled arabinogalactan as MRI contrast agent, Magn. Reson. Imaging 12 (1994) 61-69.
144. H. Ahlstrom, H.B. Gehl, Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging, Acta Radiol. 38 (1997) 660-664.
145. C. Curtet, C. Bourgoin, J. Bohy, J.C. Saccavini, P. Thedrez, S. Akoka, C. Tellier, J.F. Chatal, Gd-25 DTPA-MAb a potential NMR contrast agent for MRI in the xenografted nude mouse: preliminary studies, Int. J. Cancer Suppl. 2 (1988) 126-132.
146. K.G. Go, J.W. Bulte, L. de Ley, T.H. The, R.L. Kamman, C.E. Hulstaert, E.H. Blaauw, L.D. Ma, Our approach towards developing a specific tumour-targeted MRI contrast agent for the brain, Eur. J. Radiol. 16 (1993) 171-175.
147. T. Suzuki, K. Nakano, K. Tomiyoshi, I. Sakata, K. Endo, H. Yamanaka, Contrast enhancement of PC-3 prostate cancer for magnetic resonance imaging: animal studies using tumor-localizing Mn-metalloporphyrin (THF-Mn-Asp), J. Urol. 156 (1996) 1850-1852.
148. Y. Ni, G. Marchal, Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities, Acta Radiol. 38 (1997) 724-731.